{
    "Trade/Device Name(s)": [
        "ARCHITECT ROMA"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K151502",
    "Predicate Device Reference 510(k) Number(s)": [
        "K103358"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "ONX"
    ],
    "Summary Letter Date": "April 18, 2016",
    "Summary Letter Received Date": "April 19, 2016",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.6050"
    ],
    "Regulation Name(s)": [
        "Ovarian adnexal mass assessment score test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "HE4",
        "CA 125"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT i2000SR system"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent microparticle immunoassay (CMIA)",
        "Software algorithm"
    ],
    "Methodologies": [
        "Algorithmic risk scoring",
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Algorithm",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for ARCHITECT ROMA software algorithm and immunoassay to assess likelihood of ovarian malignancy in women with adnexal masses",
    "Indications for Use Summary": "Intended to aid in assessing whether a premenopausal or postmenopausal woman presenting with an ovarian adnexal mass is at high or low likelihood of malignancy at surgery; not for screening or stand-alone diagnosis; result must be interpreted with clinical and radiological assessment",
    "fda_folder": "Obstetrics"
}